Cancer
Conditions
Keywords
Fatigue, Cancer
Brief summary
This investigator-initiated study aims to evaluate the incidence and severity of cancer-related fatigue (CRF) in patients with malignant tumors, to analyze the influencing factors of CRF, and to explore its impact on anti-tumor treatment and prognosis.
Detailed description
This investigator-initiated study aims to evaluate the incidence and severity of cancer-related fatigue (CRF) in patients with malignant tumors, to analyze the influencing factors of CRF, and to explore its impact on anti-tumor treatment and prognosis. Using patient-completed questionnaires, combined with outpatient visit records and telephone follow-up, this study will explore the following aspects: Assess the incidence and severity of cancer-related fatigue in patients with malignant tumors. Analyze the influencing factors of cancer-related fatigue, including tumor type, treatment regimen, disease stage, efficacy of anti-tumor therapy, adverse events associated with anti-tumor therapy, and concomitant medications. Evaluate the impact of cancer-related fatigue on anti-tumor treatment and prognosis. Assess the multidimensional state and severity of cancer-related fatigue in patients with malignant tumors using the Brief Fatigue Inventory - Cancer (BFI-C) and the Multidimensional Fatigue Symptom Inventory - Short Form (MFSI-SF). By collecting patients' medical information, including imaging and laboratory results, as well as outpatient and telephone follow-up records, this study will explore the following aspects: Evaluate the impact of different degrees of cancer-related fatigue on the prognosis of patients with malignant tumors. Explore the impact of the efficacy of anti-tumor therapy on the multidimensional state and severity of cancer-related fatigue in patients.
Interventions
OTHERNo Interventions
No Interventions
Sponsors
Fudan University
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female, aged 18 years or older. 2. Able to understand the purpose of this survey study, willing to participate, and able to sign an informed consent form. 3. Malignant tumor confirmed histologically or cytologically.
Exclusion criteria
1. Pregnant or breastfeeding women. 2. Patients with acute or chronic infections, or those with other serious medical conditions that, in the investigator's judgment, make them unsuitable for this study. 3. Patients with two or more concurrent malignant tumors (excluding the following: cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and papillary thyroid carcinoma). 4. Patients with psychiatric illness or mental disorders, poor compliance, or who are unable to cooperate and report treatment responses. 5. Patients with severe organic disease or major organ failure, such as decompensated heart, lung, liver, or kidney failure. 6. Patients with other conditions that, in the investigator's opinion, make them unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of cancer-related fatigue (CRF) in tumor patients. | Baseline | The incidence of cancer-related fatigue (CRF) in tumor patients. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The severity grading of cancer-related fatigue (CRF) in tumor patients across different tumor types and multiple treatment settings. | Baseline | The severity grading of cancer-related fatigue (CRF) in tumor patients across different tumor types and multiple treatment settings. |
| The correlation between treatment regimen and the incidence of cancer-related fatigue (CRF). | Baseline | — |
| The incidence of anti-tumor treatment delays, dose reductions, or regimen modifications due to cancer-related fatigue (CRF). | Baseline | — |
| Progression-free survival (PFS) and overall survival (OS) in patients with different grades of cancer-related fatigue (CRF) undergoing anti-tumor therapy. | Baseline | — |
| To assess the state and severity of cancer-related fatigue (CRF) in patients with malignant tumors using the Brief Fatigue Inventory - Cancer (BFI-C) and the Multidimensional Fatigue Symptom Inventory - Short Form (MFSI-SF). | Baseline | — |
Countries
China
Contacts
CONTACTHongxia Wang, PhD
CONTACTJuan Jin, PhD
Outcome results
None listed